Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Lifestyle Intervention Is Superior To Metformin In Prevention Of Microvascular Complications Of Diabetes In Women, But Socioeconomic Barriers May Lead To Use Of Combination, Katanya C. Alaga, Jesse Haddad
Lifestyle Intervention Is Superior To Metformin In Prevention Of Microvascular Complications Of Diabetes In Women, But Socioeconomic Barriers May Lead To Use Of Combination, Katanya C. Alaga, Jesse Haddad
Clinical Research in Practice: The Journal of Team Hippocrates
A clinical decision report using
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-875. https://doi.org/10.1016/S2213-8587(15)00291-0
for a patient with pre-diabetes who is concerned about the prevention of microvascular complications through lifestyle intervention while managing her busy schedule as a traveling house cleaner.
Pre-Mixed Insulin Has A Similar Efficacy To Basal-Bolus Insulin In Reducing Hba1c Levels In Type 2 Diabetics, Rujuta Patil
Pre-Mixed Insulin Has A Similar Efficacy To Basal-Bolus Insulin In Reducing Hba1c Levels In Type 2 Diabetics, Rujuta Patil
Clinical Research in Practice: The Journal of Team Hippocrates
A clinical decision report using:
Fulcher G, Roberts A, Sinha A, Proietto J. What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. Diabetes Research and Clinical Practice, 2015;108(3):405–413. https://doi.org/10.1016/j.diabres.2015.03.004
for a patient with uncontrolled type 2 diabetes.
Starting Triple Oral Hypoglycemic Agent Therapy In Poorly Controlled Type 2 Diabetes Is A Suitable Therapeutic Strategy To Lower Hba1c When Insulin Therapy Is Not Desired, Mara A. Darian
Clinical Research in Practice: The Journal of Team Hippocrates
A clinical decision report using:
Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care. 2016;40(2):201-209. https://doi.org/10.2337/dc16-1347
for a patient with uncontrolled type 2 diabetes on metformin and sitagliptin and hesitant to begin insulin therapy.